PMID: 15244250Jul 13, 2004Paper

A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides

Acta Oncologica
V TolmachevHans Lundqvist

Abstract

Advances in diagnostics and targeted radionuclide therapy of haematological and neuroendocrine tumours have raised hope for improved radionuclide therapy of other forms of disseminated tumours. New molecular target structures are characterized and this stimulates the efforts to develop new radiolabelled targeting agents. There is also improved understanding of factors of importance for choice of appropriate radionuclides. The choice is determined by physical, chemical, biological, and economic factors, such as a character of emitted radiation, physical half-life, labelling chemistry, chemical stability of the label, intracellular retention time, and fate of radiocatabolites and availability of the radionuclide. There is actually limited availability of suitable radionuclides and this is a limiting factor for further progress in the field and this is the focus in this article. The probably most promising therapeutic radionuclide, 211At, requires regional production and distribution centres with dedicated cyclotrons. Such centres are, with a few exceptions in the world, lacking today. They can be designed to also produce beta- and Augeremitters of therapeutic interest. Furthermore, emerging satellite PET scanners will in the near...Continue Reading

References

Jul 1, 1990·International Journal of Radiation Biology·T E Wheldon, J A O'Donoghue
Jan 1, 1990·International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology·G B SahaD R Neumann
Nov 1, 1990·The New England Journal of Medicine·S W LambertsE P Krenning
Jan 1, 1988·International Journal of Radiation Applications and Instrumentation. Part A, Applied Radiation and Isotopes·M R Zalutsky, A S Narula
Nov 3, 1995·International Journal of Cancer. Journal International Du Cancer·M EssandJ Carlsson
Jan 1, 1994·Breast Cancer Research and Treatment·J Baselga, J Mendelsohn
Jan 1, 1993·Journal of Cancer Research and Clinical Oncology·M W BeckmannJ A Holt
Oct 1, 1996·Physics in Medicine and Biology·J Zweit
Oct 1, 1996·Physics in Medicine and Biology·J A O'Donoghue, T E Wheldon
Jan 1, 1997·Nuclear Medicine and Biology·D W McCarthyM J Welch
Sep 2, 1998·European Journal of Nuclear Medicine·M R McDevittD A Scheinberg
Feb 13, 1999·International Journal of Cancer. Journal International Du Cancer·S BraunK Pantel
Dec 10, 1999·Clinics in Chest Medicine·J J Erasmus, E F Patz
Dec 22, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·M BalzarS V Litvinov
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·S J KennelS Mirzadeh
Jun 16, 2000·Radiologic Clinics of North America·S J Goldsmith, L Kostakoglu
Jun 16, 2000·Cancer Metastasis Reviews·C J WikstrandD D Bigner
Jul 21, 2000·Current Pharmaceutical Design·M R Zalutsky, G Vaidyanathan
Jul 27, 2000·Current Medicinal Chemistry·A HeppelerH R Maecke
Feb 28, 2001·Expert Opinion on Investigational Drugs·E H Holmes
May 8, 2001·International Journal of Cancer. Journal International Du Cancer·M de JongE P Krenning
Dec 26, 2001·Chemical Reviews·W A Volkert, T J Hoffman
Jan 16, 2002·Current Opinion in Oncology·Wouter W de Herder, Steven W J Lamberts
Apr 20, 2002·Seminars in Nuclear Medicine·Lowell B AnthonyKevin E McCarthy
May 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J C LeeH-B Yang
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert O Dillman
Oct 18, 2002·Expert Review of Anticancer Therapy·Antonio J Grillo-López
Oct 24, 2002·Blood·Bruce D Cheson
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·G BlackledgeJ Barton
Feb 6, 2003·Journal of the National Cancer Institute·Ken Garber
Mar 14, 2003·European Journal of Nuclear Medicine and Molecular Imaging·D J KwekkeboomE P Krenning
Mar 22, 2003·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jörgen CarlssonJan Tennvall

❮ Previous
Next ❯

Citations

Aug 31, 2007·Chemotherapy·Shyama K ShuklaRoberto Cusumano
Jul 27, 2007·Cancer Biotherapy & Radiopharmaceuticals·Roy H LarsenOyvind S Bruland
Aug 8, 2009·AJNR. American Journal of Neuroradiology·J J CuaronA E Hirsch
Jun 13, 2009·Journal of Receptor and Signal Transduction Research·Alex N Eberle, Gabriele Mild
Aug 16, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Sture LindegrenHolger Jensen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.